Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 1909258, 11 pages
https://doi.org/10.1155/2017/1909258
Review Article

Molecular Mechanisms and Treatment Strategies in Diabetic Nephropathy: New Avenues for Calcium Dobesilate—Free Radical Scavenger and Growth Factor Inhibition

1Department of Nephrology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
2Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China

Correspondence should be addressed to Hermann Haller; ed.revonnah-hm@nnamreh.rellah

Received 13 March 2017; Accepted 21 June 2017; Published 26 September 2017

Academic Editor: Hans Baelde

Copyright © 2017 Hermann Haller et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Gustafson, B. Heubner, K. Lamb et al., “United States renal data system 2011 annual data report: atlas of chronic kidney disease & end-stage renal disease in the United States,” American Journal of Kidney Disease, vol. 59, 1, no. 1, pp. e1–e420, 2012. View at Google Scholar
  2. C. E. Mogensen, “Microalbuminuria as a predictor of clinical diabetic nephropathy,” Kidney International, vol. 31, no. 2, pp. 673–689, 1987. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Fioretto and M. Mauer, “Histopathology of diabetic nephropathy,” Seminars in Nephrology, vol. 27, no. 2, pp. 195–207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. M. Berhane, E. J. Weil, W. C. Knowler, R. G. Nelson, and R. L. Hanson, “Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 10, pp. 2444–2451, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Hovind, P. Rossing, L. Tarnow, U. M. Smidt, and H. H. Parving, “Progression of diabetic nephropathy,” Kidney International, vol. 59, no. 2, pp. 702–709, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. N. R. Robles, E. Fernández-Carbonero, E. S. Casado, and J. Cuberto, “Growing incidence of diabetic nephropathy in the region of Badajoz during the period 1991–2006,” Nefrologia, vol. 29, no. 3, pp. 244–248, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. G. Nelson, J. M. Newman, W. C. Knowler et al., “Incidence of end-stage renal disease in Type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians,” Diabetologia, vol. 31, no. 10, pp. 730–736, 1988. View at Publisher · View at Google Scholar · View at Scopus
  8. T. W. C. Tervaert, A. L. Mooyaart, K. Amann et al., “Pathologic classification of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 21, no. 4, pp. 556–563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. D. D. Gellman, C. L. Pirani, J. F. Soothill, R. C. Muehrcke, and R. M. Kark, “Diabetic nephropathy: A clinical and pathologic study based on renal biopsies,” Medicine (United States), vol. 38, no. 4, pp. 321–367, 1959. View at Google Scholar · View at Scopus
  10. A. Bohle, M. Wehrmann, O. Bogenschutz, C. Batz, C. A. Muller, and G. A. Muller, “The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis,” Pathology Research and Practice, vol. 187, no. 2-3, pp. 251–259, 1991. View at Publisher · View at Google Scholar · View at Scopus
  11. C. S. Chang, A. H. Yang, and C. H. Chang, “Nodular glomerulosclerosis mimicking diabetic nephropathy without overt diabetes mellitus,” Clinical Nephrology, vol. 64, no. 4, pp. 300–304, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. G. S. Markowitz, J. Lin, A. M. Valeri, C. Avila, S. H. Nasr, and V. D. D'Agati, “Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking,” Human Pathology, vol. 33, no. 8, pp. 826–835, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. L. C. Stout, S. Kumar, and E. B. Whorton, “Insudative lesions—their pathogenesis and association with glomerular obsolescence in diabetes: a dynamic hypothesis based on single views of advancing human diabetic nephropathy,” Human Pathology, vol. 25, no. 11, pp. 1213–1227, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. S. D. Navaneethan, S. Singh, and W. Choudhry, “Nodular glomerulosclerosis in a non-diabetic patient: case report and review of literature,” Journal of Nephrology, vol. 18, no. 5, pp. 613–615, 2005. View at Google Scholar · View at Scopus
  15. R. Osterby, H. J. Bangstad, G. Nyberg, J. D. Walker, and G. Viberti, “The structure of glomeruli and juxtaglomerular arterioles in the early phase of diabetic nephropathy—relationship between progression and metabolic control,” Contributions to Nephrology, vol. 118, pp. 195–205, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Lane, M. W. Steffes, and S. M. Mauer, “Structural-functional relationships in type I insulin-dependent diabetes mellitus in humans,” Journal of Diabetic Complications, vol. 5, no. 2-3, pp. 69–71, 1991. View at Publisher · View at Google Scholar · View at Scopus
  17. G. L. King, T. Shiba, J. Oliver, T. Inoguchi, and S. E. Bursell, “Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus,” Annual Review of Medicine, vol. 45, pp. 179–188, 1994. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Nakagawa, K. Tanabe, B. P. Croker et al., “Endothelial dysfunction as a potential contributor in diabetic nephropathy,” Nature Reviews Nephrology, vol. 7, no. 1, pp. 36–44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. S. C. Satchell and J. E. Tooke, “What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?” Diabetologia, vol. 51, no. 5, pp. 714–725, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. D. M. Stern, C. Esposito, H. Gerlach et al., “Endothelium and regulation of coagulation,” Diabetes Care, vol. 14, no. 2, pp. 160–166, 1991. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Verhamme and M. F. Hoylaerts, “The pivotal role of the endothelium in haemostasis and thrombosis,” Acta Clinica Belgica, vol. 61, no. 5, pp. 213–219, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Garsen, A. L. Rops, T. J. Rabelink, J. H. Berden, and J. van der Vlag, “The role of heparanase and the endothelial glycocalyx in the development of proteinuria,” Nephrology Dialysis Transplantation, vol. 29, no. 1, pp. 49–55, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. D. D. Wagner and P. S. Frenette, “The vessel wall and its interactions,” Blood, vol. 111, no. 11, pp. 5271–5281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. David, H. Haller, and P. Kümpers, “The angiopoietin/tie-2 axis: a novel player in chronic kidney disease,” Minerva Urologica e Nefrologica, vol. 62, no. 3, pp. 319–326, 2010. View at Google Scholar · View at Scopus
  25. C. Dessapt-Baradez, A. S. Woolf, K. E. White et al., “Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease,” Journal of the American Society of Nephrology, vol. 25, no. 1, pp. 33–42, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. T. S. Saurabh, B. D. Johnson, J. D. Johnston, and J. P. Wallace, “Sitting and endothelial dysfunction: the role of shear stress,” Medical Science Monitor, vol. 18, no. 12, pp. RA173–RA180, 2012. View at Publisher · View at Google Scholar
  27. P. Mohanty, W. Hamouda, R. Garg, A. Aljada, H. Ghanim, and P. Dandona, “Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 8, pp. 2970–2973, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Tripathy, P. Mohanty, S. Dhindsa et al., “Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects,” Diabetes, vol. 52, no. 12, pp. 2882–2887, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. R. R. Foster, R. Hole, K. Anderson et al., “Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes,” American Journal of Physiology Renal Physiology, vol. 284, no. 6, pp. F1263–F1273, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Ferrara, H. P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Sison, V. Eremina, H. Baelde et al., “Glomerular structure and function require paracrine , not autocrine, VEGF-VEGFR-2 signaling,” American Journal of Nephrology, vol. 21, pp. 1691–1701, 2010. View at Google Scholar
  32. G. A. Sivaskandarajah, M. Jeansson, Y. Maezawa, V. Eremina, H. J. Baelde, and S. E. Quaggin, “Vegfa protects the glomerular microvasculature in diabetes,” Diabetes, vol. 61, no. 11, pp. 2958–2966, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Eremina, J. A. Jefferson, J. Kowalewska et al., “VEGF inhibition and renal thrombotic microangiopathy,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1129–1136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. M. E. Cooper, D. Vranes, S. Youssef et al., “Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes,” Diabetes, vol. 48, no. 11, pp. 2229–2239, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. H. J. Baelde, M. Eikmans, D. W. Lappin et al., “Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss,” Kidney International, vol. 71, no. 7, pp. 637–645, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Hohenstein, B. Hausknecht, K. Boehmer, R. Riess, R. A. Brekken, and C. P. Hugo, “Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man,” Kidney International, vol. 69, no. 9, pp. 1654–1661, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Oltean, Y. Qiu, J. K. Ferguson et al., “Vascular endothelial growth factor-A165b is protective and restores endothelial glycocalyx in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 26, no. 8, pp. 1889-1890, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. F. S. Grünewald, A. E. Prota, A. Giese, and K. Ballmer-Hofer, “Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling,” Biochimica et Biophysica Acta: Proteins and Proteomics, vol. 1804, no. 3, pp. 567–580, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Daehn and E. P. Bottinger, “Microvascular endothelial cells poised to take center stage in experimental renal fibrosis,” Journal of the American Society of Nephrology, vol. 26, no. 4, pp. 767–776, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Flyvbjerg, F. Dagnæs-Hansen, A. S. De Vriese, B. F. Schrijvers, R. G. Tilton, and R. Rasch, “Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody,” Diabetes, vol. 51, no. 10, pp. 3090–3094, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Calles-Escandon and M. Cipolla, “Diabetes and endothelial dysfunction: a clinical perspective,” Endocrine Reviews, vol. 22, no. 1, pp. 36–52, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. Diabetes Control and Complications Trial Research Group, “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” N Engl J Med, vol. 329, pp. 977–986, 1993. View at Google Scholar
  43. H. Y. Wu, J. W. Huang, H. J. Lin et al., “Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis,” BMJ, vol. 347, Article ID f6008, 2013. View at Google Scholar
  44. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, “Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus,” Journal of the American Medical Association, vol. 287, no. 19, pp. 2563–2569, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Y. Wu, J. W. Huang, H. J. Lin et al., “Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis,” BMJ, vol. 347, Article ID f6008, 2013. View at Publisher · View at Google Scholar
  46. H. Haller, S. Ito, J. L. Izzo Jr. et al., “Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes,” The New England Journal of Medicine, vol. 364, no. 10, pp. 907–917, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Menne, E. Ritz, L. M. Ruilope, C. Chatzikyrkou, G. Viberti, and H. Haller, “The randomized olmesartan and diabetes microalbuminuria prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation,” Journal of the American Heart Association, vol. 3, no. 2, Article ID e000810, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Suschek, H. Kolb, and V. Kolb-Bachofen, “Dobesilate enhances endothelial nitric oxide synthase-activity in macro- and microvascular endothelial cells,” British Journal of Pharmacology, vol. 122, no. 7, pp. 1502–1508, 1997. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Brunet, J.-C. Farine, R. P. Garay, and P. Hannaert, “Angioprotective action of CaD against the increased capillary permeability induced by reactive oxygen species in the rat cavity,” European Journal of Pharmacology, vol. 358, no. 3, pp. 213–220, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Hannaert, J. Brunet, J. C. Farine, and R. P. Garay, “Antioxidant-angioprotective actions of CaD in diabetic rats,” International Journal of Angiology, vol. 8, no. 1, pp. S2–S4, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. E. C. Leal, J. Martins, P. Voabil et al., “CaD inhibits the alterations in tight junction proteins and leucocyte adhesion to retinal endothelial cells induced by diabetes,” Diabetes, vol. 59, no. 10, pp. 2637–2645, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Tesfamariam and R. A. Cohen, “Free radicals mediate endothelial cell dysfunction caused by elevated glucose,” American Journal of Physiology - Heart and Circulatory Physiology, vol. 263, no. 2, pp. H321–H326, 1992. View at Google Scholar · View at Scopus
  53. J. Brunet, J. C. Farine, R. P. Garay, and P. Hannaert, “In vitro antioxidant properties of calcium dobesilate,” Fundam Clin Pharmacol, vol. 12, no. 2, pp. 205–212, 1998. View at Google Scholar
  54. E. Ruiz, R. Lorente, and T. Tejerina, “Effects of CaD on the synthesis of endothelium – dependent relaxing factors in rabbit isolated aorta,” British Journal of Pharmacology, vol. 121, no. 4, pp. 711–716, 1997. View at Publisher · View at Google Scholar · View at Scopus
  55. M. E. Szabo, D. Haines, E. Garay et al., “Antioxidant properties of CaD in ischemic/reperfused diabetic rat retina,” European Journal of Pharmacology, vol. 428, no. 2, pp. 277–286, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. R. Rota, C. Chiavaroli, R. P. Garay, and P. Hannaert, “Reduction of retinal albumin leakage by the antioxidant CaD in streptozotocin-diabetic rats,” European Journal of Pharmacology, vol. 495, no. 2-3, pp. 217–224, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. N. B. Piller, “Assessment of the anti-inflammatory action of CaD. Effect on macrophage attaching to subcutaneously implanted coverslips in guinea pigs,” Arzneimittel-Forschung/Drug Research, vol. 40, no. 6, pp. 698–700, 1990. View at Google Scholar · View at Scopus
  58. J. Angulo, C. Peiró, T. Romacho et al., “Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate,” European Journal of Pharmacology, vol. 667, no. 1-3, pp. 153–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Cuevas, I. Sanchez, R. M. Lozano, and G. Gimenez-Gallego, “Dobesilate is an angiogenesis inhibitor,” European Journal of Medical Research, vol. 10, pp. 369–372, 2005. View at Google Scholar
  60. I. S. Fernandez, P. Cuevas, J. Angulo et al., “Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors,” Journal of Biological Chemistry, vol. 285, no. 15, pp. 11714–11729, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Loges, M. Mazzone, P. Hohensinner, and P. Carmeliet, “Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited,” Cancer Cell, vol. 15, no. 3, pp. 167–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Dong, X. Liu, S. Liu, M. Li, Y. Xu, and B. Cui, “Effects of CaD on glomerulus TIMP1 and collagen IV of diabetic rats,” Journal Huazhong University of Science Tecnology and Medical Sciences, vol. 25, no. 416, 2005. View at Google Scholar
  63. J. Dong et al., “CaD in the treatment of early diabetic nephropathy,” Journal of Shandong University, vol. 46, pp. 80–83, 2008. View at Google Scholar
  64. M. Jafarey, S. Changizi Ashtiyani, and H. Najafi, “CaD for prevention of gentamicin-induced nephrotoxicity in rats,” Iranian Journal of Kidney Disease, vol. 8, pp. 46–52, 2014. View at Google Scholar
  65. X. Zhang, “Therapeutic effects of CaD on diabetic nephropathy mediated through reduction of expression of PAI-1,” Experimental and Therapeutic Medicine, vol. 5, no. 1, pp. 295–299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Dong, X. Q. Zhang, and C. G. Liang, “Therapeutic effect comparison between CaD and perindopril in treatment of early diabetic nephropathy,” Chinese General Practice, vol. 14, pp. 1232–1236, 2008. View at Google Scholar
  67. Y. Xia, X.-Y. Li, and y. Zhang, “Effects of CaD on microinflammatory state in maintenance hemodialysis patients,” Chinese Journal of Blood Purification, vol. 5, pp. 829–831, 2006. View at Google Scholar
  68. Y. Zhou and G. Xiaozhen, “Clinical observation on CaD combined with perindopril in the treatment of patients with early diabetic nephropathy,” Nephropathy Medical Frontier, vol. 23, 2013. View at Google Scholar
  69. X. Zheng, Z.-X. Hu, and Y.-H. Zhang, “Curative effect of benazepril combined with CaD on diabetic nephropathy,” Hainan Medical Journal, vol. 23, pp. 33-34, 2012. View at Google Scholar
  70. X. Zheng, Z. X. Hu, Y. H. Zhang et al., “The efficacy of CaD combined enalapril on diabetic nephropathy proteinuria,” Sichuan Medical Journal, vol. 34, pp. 1249-1250, 2013. View at Google Scholar
  71. M. Jin, “Clinical observation on effect of CaD combined with losartan potassium on proteinuria in patients with diabetic nephropathy,” Chinese Journal of New Clinical Medicine, vol. 8, 2015. View at Google Scholar
  72. L. Chen and R. Yang, “Effects of CaD in patients with diabetic nephropathy,” Medical Journal of Wuhan University, vol. 32, 2011. View at Google Scholar
  73. L. Li, A. Qin, X. Zhao, W. Li, K. Chen, and Z. Tang, “Treatment efficacy on early type 2 diabetic nephropathy with CaD,” Chinese Journal of Clinical Pharmacology, vol. 29, pp. 900–902, 2013. View at Google Scholar